Clinical trials: Generalized Anxiety Disorder
Anxiety Disorders
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
- Trial name
- NCT00715039
- Testing
- lorazepam, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD, Anxiety Disorder, Generalized
Serotonin Variants & Gut Microbiota in Mental Health
This observational pilot study investigates whether a broad panel of genetic variants relevant to the serotonin pathway (including serotonergic system, methylation cycle, intestinal barrier integrity, and inflammatory response…
- Conditions
- Major Depressive Disorder (MDD, Anxiety Disorder, Generalized, Stress Disorders, Post-Traumatic, Panic Disorder
- Trial name
- NCT07634458
- Testing
- SNP Genotyping and Gut Metagenomics
- Volunteers
- 30 people
- Sponsor
- Neurobiologix
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg and 700 mg dose of SR58611A compared to…
- Trial name
- ELECTRA (NCT00332891)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Croatia and 3 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)
The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.
- Trial name
- NCT00703833
- Testing
- MK0777
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Anxiety Disorder
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old.
- Trial name
- NCT05729373
- Testing
- SEP-363856
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 434 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Anxiety Disorders
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.
- Trial name
- NCT00389064
- Testing
- Quetiapine XR
- Where
- 43 sites in United States, Estonia and 3 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Anxiety Disorders
Therapeutic Effect of an Herbal Medicine on Anxiety
Phase III, double blind, randomized study, controlled by Valeriana officinalis L for evaluating the efficacy of association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L. in generalized anxiety disorder.
- Trial name
- NCT01178632
- Testing
- Passiflora, Valeriana officinalis
- Where
- Brazil
- Volunteers
- 136 people
- Sponsor
- Millet Roux
Anxiety Disorders
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00807937
- Testing
- AZD7325, Lorazepam
- Where
- 51 sites in United States
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- VLZ-MD-06 (NCT01766401)
- Testing
- Vilazadone
- Where
- 30 sites in United States
- Volunteers
- 402 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this study is to assess how safe ITI-1284 is and how well it can be tolerated in long-term, when given alone or with other medicines, in participants with generalized anxiety disorder (GAD) who have not responded…
- Trial name
- NCT07807865
- Testing
- ITI-1284
- Where
- 3 sites in United States
- Volunteers
- 900 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
General Anxiety Disorder
A Dose-Response Safety Study of ENX-102 in Patients With GAD
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD
- Trial name
- NCT06653296
- Testing
- ENX-102
- Where
- 3 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Engrail Therapeutics INC
Generalized Anxiety Disorder
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
- Trial name
- NCT06051721
- Testing
- CYB004, Psychotherapy
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Cybin IRL Limited
Generalized Anxiety Disorder
Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder.
- Trial name
- NCT06010654
- Testing
- Software as a Medical device
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- HAII corp.ltd
Generalized Anxiety Disorder
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
- Trial name
- ENCALM (NCT05749055)
- Testing
- ENX-102
- Where
- 32 sites in United States
- Volunteers
- 252 people
- Sponsor
- Engrail Therapeutics INC
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Anxiety Disorders
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.
- Trial name
- NCT00214994
- Testing
- Gabitril
- Where
- 93 sites in United States, Canada
- Sponsor
- Cephalon
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Generalized Anxiety Disorder
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder…
- Trial name
- NCT07856420
- Testing
- JNJ-99245354
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Anxiety Disorders
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00808249
- Testing
- AZD7325
- Where
- 52 sites in United States
- Volunteers
- 725 people
- Sponsor
- AstraZeneca